ReviewEndocrine oncology (Bristol, England)2024
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations.
Abstract readReview
In one paragraph
Review in Endocrine oncology (Bristol, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- IL-1β/CXCL12 signalling orchestrates adipocyte-pancreatic neuroendocrine tumor crosstalk.Journal of translational medicine · 2026Article
- Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model.Endocrine-related cancer · 2026Article
- Metformin suppresses MEN1-associated pancreatic and pituitary neuroendocrine tumors: evidence from mouse models and clinical data.Endocrine-related cancer · 2026Article
- Adaphostin-induced oxidative stress in oesophageal neuroendocrine carcinoma: a potential therapeutic strategy.Medical oncology (Northwood, London, England) · 2026Article
- Overcoming resistance in lung cancer: combined mitochondrial destabilization by lipophilic cations and doxycycline in hypoxic non-small cell lung carcinoma.Frontiers in pharmacology · 2026Article
- Review
- Loss of MBD2 is associated with tumor growth in small intestinal neuroendocrine tumors.Endocrine connections · 2025Article
- Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior.The American journal of case reports · 2025Article
- Incidence and risk factors for insulinoma diagnosed in dogs under primary veterinary care in the UK.Scientific reports · 2025Article
- Incidence and risk factors for phaeochromocytoma diagnosis in dogs under primary veterinary care in the UK.PloS one · 2025Article
- Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies.Endocrine oncology (Bristol, England) · 2025Article
- Single-cell transcriptome conservation in a multispecies comparative analysis of fresh and cryopreserved insulinoma cell lines.Veterinary oncology (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Po Hien EarDepartment of Surgery, University of Iowa, Iowa City, Iowa, USA.ORCID https://orcid.org/0000-0003-0823-9166
Ilaria MarinoniInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Talya DaytonEuropean Molecular Biology Laboratory (EMBL) Barcelona, Tissue Biology and Disease Modelling, Barcelona, Spain.
Rachael GuenterDepartment of Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-1024-7037
Dawn E QuelleDepartment of Neuroscience and Pharmacology, University of Iowa, Iowa City, Iowa, USA.
Anna BattistellaPancreatic Surgery Unit, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Floryne O BuishandDepartment of Clinical Science and Services, Royal Veterinary College, Hatfield, UK.
Suganthi ChittaranjanDepartment of Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
Yi-Cheih Nancy DuDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
Ines MarquesInstitute of Anatomy, University of Bern, Bern, Switzerland.
Natalia S PellegataDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Samira M SadowskiEndocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-7538-9431
Amit TiroshENTIRE - Endocrine Neoplasia Translational Research Center, Sheba Medical Center, and Tel Aviv University Faculty of Medicine, Tel Aviv, Israel.ORCID https://orcid.org/0000-0003-3794-9634
Simon April-MonnDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Cinzia AuriliaAssociazione Italiana Neoplasie Endocrine Multiple di tipo 1 e di tipo 2 (AIMEN 1 e 2), Sondrio, Italy.
Renata Jaskula-SztulDepartment of Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Maria Jesús Baena MorenoCenter of Experimental Oncology, Gastrointestinal and Neuroendocrine Tumors Research Group, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain.
Simone DonatiAssociazione Italiana Neoplasie Endocrine Multiple di tipo 1 e di tipo 2 (AIMEN 1 e 2), Sondrio, Italy.
Katherine A EnglishOCDEM, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford, UK.ORCID https://orcid.org/0000-0003-1439-1834
Maria Almudena Hernandez LlorensCenter of Experimental Oncology, Gastrointestinal and Neuroendocrine Tumors Research Group, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain.ORCID https://orcid.org/0000-0003-2543-5038
Harry HodgettsRegenerative Medicine and Fibrosis Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, UK.ORCID https://orcid.org/0009-0003-9498-1961
Francesca MariniFIRMO Foundation (Italian Foundation for the Research on Bone Diseases), Florence, Italy.
Maria MartinsRegenerative Medicine and Fibrosis Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, UK.
Gaia PalminiFIRMO Foundation (Italian Foundation for the Research on Bone Diseases), Florence, Italy.
Beatriz SoldevillaCenter of Experimental Oncology, Gastrointestinal and Neuroendocrine Tumors Research Group, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain.ORCID https://orcid.org/0000-0002-1118-1316
Jörg SchraderDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Rajesh V ThakkerOCDEM, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford, UK.
Kate E LinesOCDEM, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford, UK.ORCID https://orcid.org/0000-0002-0764-8681
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current models for the study of neuroendocrine tumours (NETs) are severely limited. While
Indexed as
consortiumex vivoin vitroin vivo
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.